Physician

Andrea Lyn Oliverio, MD

According to 2025 Medicare claims, Andrea Oliverio, MD (NPI: 1982997813) practices nephrology in the Ann Arbor, MI market, with the plurality of this provider's patient population coming from Washtenaw, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1003848144; TIN: 386006309) and primary practice location at 48109-5000. Oliverio is affiliated with the POM ACO (ACO ID: A1297), participating under the MSSP model.

Oliverio's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 75 traditional Medicare patients, billed 168 HCPCS/CPT codes, and received $13,704 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 279 prescription claims across 40 beneficiaries totaling $52,726 in drug costs, led by Envarsus Xr (Tacrolimus). DME data shows 96 claims. Open Payments data shows 4 records totaling $5,105. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $5,358 and ending at $13,704. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $6,521 to $52,726. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	49	76	$5,358
2018	170	472	$36,836
2019	140	366	$28,321
2020	143	382	$36,463
2021	103	208	$29,589
2022	126	312	$41,450
2023	101	212	$31,177
2024	75	168	$13,704

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	38	135	$6,521
2016	42	116	$6,623
2017	34	171	$6,717
2018	31	188	$7,175
2019	38	216	$6,200
2020	36	181	$33,308
2021	45	207	$16,099
2022	42	214	$23,621
2023	41	218	$32,792
2024	40	279	$52,726

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	14	$6,456
2022	N/R	27	$7,751
2023	N/R	83	$10,994
2024	N/R	96	$13,569

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	12	17	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	18	20	$76
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	24	38	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	32	39	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Envarsus Xr	Tacrolimus	25	750	$13,705
Metoprolol Succinate	Metoprolol Succinate	17	1,327	$408
Lisinopril	Lisinopril	35	2,790	$370
Valsartan	Valsartan	13	376	$311
Amlodipine Besylate	Amlodipine Besylate	26	2,136	$193

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	24	$12,387
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$590
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$358
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	14	$225
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	13	$10

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$5,105	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrea Lyn Oliverio, MD?

Tedicare shows public-source Medicare data for Andrea Lyn Oliverio, MD (NPI 1982997813), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrea Lyn Oliverio, MD have ACO affiliation data?

Andrea Lyn Oliverio, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297).

What billing organization is linked to Andrea Lyn Oliverio, MD?

Andrea Lyn Oliverio, MD is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1003848144) in the available physician profile data.

Does Andrea Lyn Oliverio, MD have Open Payments data?

Andrea Lyn Oliverio, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.